{"id":861,"date":"2024-08-30T22:59:36","date_gmt":"2024-08-30T20:59:36","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/bilim-ve-uygulamadan-guencel-gelismeler\/"},"modified":"2026-07-22T12:01:36","modified_gmt":"2026-07-22T10:01:36","slug":"bilim-ve-uygulamadan-guencel-gelismeler","status":"publish","type":"page","link":"https:\/\/studienportal-endometriumkrebs.de\/tr\/bilim-ve-uygulamadan-guencel-gelismeler\/","title":{"rendered":"Bilim ve Uygulamadan G\u00fcncel Geli\u015fmeler"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Haberler<\/strong>
Bilim ve Uygulamadan G\u00fcncel Geli\u015fmeler<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

ASCO 2026’dan Yeni Bulgular<\/a><\/h3><\/header>
\n

NOGGO Jinekolojik Onkoloji G\u00fcncellemesi kapsam\u0131nda, bu y\u0131lki ASCO Kongresi’ne ait en \u00f6nemli \u00e7al\u0131\u015fmalar sunuldu. RUBY \u00c7al\u0131\u015fmas\u0131: \u0130mm\u00fcnoterapinin Uzun Vadeli Faydas\u0131 Do\u011fruland\u0131 RUBY \u00c7al\u0131\u015fmas\u0131‘ndan elde edilen yeni uzun vadeli veriler, dMMR-Endometrium...<\/p>devam\u0131n\u0131 oku<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

DESTINY-ENDOMETRIAL01<\/a><\/h3><\/header>
\n

DESTINY-ENDOMETRIAL01 \u0130LER\u0130 EVRE VEYA N\u00dcKS EDEN GEB\u00c4RMUTTERSCHLEIMHAUTKREBS (ENDOMETR\u0130YUM KANSER\u0130) OLAN HASTALARDA TRASTUZUMAB DERUXTECAN (T-DXD) VE RILVEGOSTOMIG VEYA PEMBROLIZUMAB KOMB\u0130NASYONUNA Y\u00d6NEL\u0130K TEDAV\u0130 \u00c7ALI\u015eMASI DESTINY-Endometrial01; t\u00fcm\u00f6r h\u00fccreleri HER2’yi a\u015f\u0131r\u0131 eksprese eden ve...<\/p>devam\u0131n\u0131 oku<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

PYNNACLE \u00c7ALI\u015eMASI<\/a><\/h3><\/header>
\n

PYNNACLE \u00c7ALI\u015eMASI LOKAL \u0130LER\u0130 EVRE VEYA METASTAT\u0130K SOL\u0130D T\u00dcM\u00d6RL\u00dc HASTALARDA YEN\u0130 ETKEN MADDE REZATAPOPT\u2019UN ETK\u0130NL\u0130K VE G\u00dcVENL\u0130L\u0130\u011e\u0130N\u0130N DE\u011eERLEND\u0130R\u0130LMES\u0130NE Y\u00d6NEL\u0130K TEDAV\u0130 \u00c7ALI\u015eMASI PYNNACLE \u00e7al\u0131\u015fmas\u0131, Rezatapopt adl\u0131 yeni bir ilac\u0131n ara\u015ft\u0131r\u0131ld\u0131\u011f\u0131 klinik...<\/p>devam\u0131n\u0131 oku<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S35 \u2013 Expression XXI \u2013 (21)<\/a><\/h3><\/header>
\n

NOGGO S35 \/ Expression XXI \u2013 (21) \/ SARA \u00c7al\u0131\u015fmas\u0131 Rahim Kanseri Olan Hastalar\u0131n Ya\u015fam Kalitesi Anketi \u00c7al\u0131\u015fmas\u0131 SARA \u00c7al\u0131\u015fmas\u0131, rahim kanseri olan hastalar\u0131n ya\u015fam kalitesine y\u00f6nelik Avrupa \u00e7ap\u0131nda bir...<\/p>devam\u0131n\u0131 oku<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

\u0130leri evre endometrium kanserlerinin tedavisi i\u00e7in yenilik\u00e7i tedavi se\u00e7enekleri<\/a><\/h3><\/header>
\n

\u0130leri evre endometrium kanserlerinin tedavisi i\u00e7in yenilik\u00e7i tedavi se\u00e7enekleri IGCS Advances & Updates’in bu \u00f6zel sunumunda, metastatik tekrarlayan rahim a\u011fz\u0131 kanseri hastas\u0131 ve hasta ara\u015ft\u0131rmalar\u0131 savunucusu Linda Ryan, klinik \u00e7al\u0131\u015fmalarla...<\/p>devam\u0131n\u0131 oku<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

HaberlerBilim ve Uygulamadan G\u00fcncel Geli\u015fmeler Neue Erkenntnisse vom ASCO 2026 Im Rahmen des NOGGO-Updates Gyn\u00e4kologische Onkologie wurden die wichtigsten Studien zum diesj\u00e4hrigen ASCO-Kongress vorgestellt.\u00a0 RUBY-Studie: Langfristiger Nutzen der Immuntherapie best\u00e4tigt Neue Langzeitdaten der\u00a0RUBY-Studie\u00a0best\u00e4tigen den anhaltenden Nutzen der Immuntherapie\u00a0Dostarlimab\u00a0in Kombination mit… devam\u0131n\u0131 oku DESTINY-ENDOMETRIAL01 DESTINY-ENDOMETRIAL01 THERAPIESTUDIE ZUR KOMBINATION VON TRASTUZUMAB DERUXTECAN (T-DXD) UND RILVEGOSTOMIG ODER PEMBROLIZUMAB […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-861","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=861"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/861\/revisions"}],"predecessor-version":[{"id":862,"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/pages\/861\/revisions\/862"}],"wp:attachment":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}